The global central nervous system therapeutics market size is expected to reach around US$ 209.2 billion by 2030 from US$ 120.64 billion in 2021 and is expected to grow at an impressive double-digit rate of 6.3% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global central nervous system therapeutics market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1523
The rising prevalence of various central nervous system diseases among the population such as Alzheimer’s disease, Parkinson’s disease, brain cancer, anxiety disorders, and epilepsy is a major factor that drives the demand for the central nervous system therapeutics.
Why should you invest in this report?
If you are aiming to enter the global central nervous system therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for central nervous system therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global central nervous system therapeutics market include:
- Biogen Inc.
- Otsuka Pharmaceutical Co. Ltd
- Eli Lilly and Company
- Merck & Co.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
- Pfizer Inc.
- GlaxoSmithKline PLC
Market Segmentation:
By Disease
- Neurovascular Diseases
- Mental Health
- Anxiety Disorders
- Mood Disorders
- Epilepsy
- Psychotic Disorders
- Others
- Neurodegenerative Diseases
- Parkinson’s Disease
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
- Multiple Sclerosis
- Huntington’s Disease
- Others
- CNS Trauma
- CNS Cancer
- Infectious Diseases
- Others
Regional Analysis:
The geographical analysis of the global central nervous system therapeutics market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global central nervous system therapeutics Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global central nervous system therapeutics market in 2030?
- What is the expected CAGR for the central nervous system therapeutics market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global central nervous system therapeutics market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Central Nervous System Therapeutic Market
5.1. COVID-19 Landscape: Central Nervous System Therapeutic Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Central Nervous System Therapeutic Market, By Disease
8.1. Central Nervous System Therapeutic Market, by Disease Type, 2020-2027
8.1.1. Neurovascular Diseases
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Mental Health
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Neurodegenerative Diseases
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. CNS Trauma
8.1.4.1. Market Revenue and Forecast (2016-2027)
8.1.5. CNS Cancer
8.1.5.1. Market Revenue and Forecast (2016-2027)
8.1.6. Infectious Diseases
8.1.6.1. Market Revenue and Forecast (2016-2027)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global Central Nervous System Therapeutic Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Disease (2016-2027)
9.1.2. U.S.
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2.3. France
9.2.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.2.4. Rest of Europe
9.2.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Disease (2016-2027)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Disease (2016-2027)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Disease (2016-2027)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Disease (2016-2027)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Disease (2016-2027)
Chapter 10. Company Profiles
10.1. Biogen Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Otsuka Pharmaceutical Co. Ltd
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Eli Lilly and Company
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Merck & Co.
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. AstraZeneca
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Takeda Pharmaceutical Company Limited
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Novartis AG
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Teva Pharmaceutical Industries Ltd.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1523
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments